AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
AbbVie(ABBV) stock is priced at $224.89, giving the company a market capitalization of 396.02B. It carries a P/E multiple of 176.13 and pays a dividend yield of 2.8%.
As of 2026-01-08, AbbVie(ABBV) stock has fluctuated between $223.12 and $231.54. The current price stands at $224.89, placing the stock +0.8% above today's low and -2.9% off the high.
The AbbVie(ABBV)'s current trading volume is 9.36M, compared to an average daily volume of 4.84M.
In the last year, AbbVie(ABBV) shares hit a 52-week high of $244.81 and a 52-week low of $164.39.
In the last year, AbbVie(ABBV) shares hit a 52-week high of $244.81 and a 52-week low of $164.39.
ABBV News
Looking at the universe of stocks we cover at Dividend Channel , in trading on Friday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 3% mark based...
Erasca Inc. (NASDAQ:ERAS) shares on Wednesday jumped close to 60% to $6.12. On Thursday, the stock fell as low as $4.33. • Erasca shares are advancing steadily...
Abbvie (ABBV) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools for...
Analyst ratings
65%
of 31 ratingsMore ABBV News
AbbVie says it’s not in talks to buy Revolution Medicines; WSJ reports another suitor may prevail AbbVie says it “is not in discussions” to acquire oncology bi...
Claim 70% Off TipRanks Premium Xilio Therapeutics ( (XLO) ) has provided an announcement. On January 8, 2026, Xilio Therapeutics reported a series of corporat...
Wolfe Research downgraded AbbVie (ABBV) to Peer Perform from Outperform without a price target The firm believes the shares already reflect expectations for out...
Wolfe Research downgraded AbbVie (ABBV) to Peer Perform from Outperform. Published first on TheFly – the ultimate source for real-time, market-moving breaking...
AbbVie Inc. ( ) will increase its dividend from last year's comparable payment on the 17th of February to $1.73. Based on this payment, the dividend yield for t...
AbbVie (ABBV) said it's not in talks to buy Revolution Medicines (RVMD). Shares of Revolution Medicines sunk 14% in after-hours trading. “AbbVie is not in disc...
HDV returned 11.3% over the past year versus 17% for the S&P 500 and underperformed by 100 percentage points over 10 years. AbbVie represents 6.2% of the fund...
